facebook
twitter
rss
account
search
search
 

Wyeth's Prevnar sales booming

Nov. 4, 2004 at 1:10 PM   |   Comments

CHICAGO, Nov. 4 (UPI) -- Prevnar, the popular drug to prevent bacterial meningitis, is on course to make more than $1 billion this year, a report says.

Sales of Prevnar, made by the pharmaceutical giant Wyeth, soared 32 percent in the third quarter to $321 million, the Chicago Tribune said Thursday.

A recent financial statement indicated this came about in part because the company made upgrades and improvements to its manufacturing facilities over the last year.

Prevnar vaccine costs about $260 for the four-shot regimen given to infants and young children. A dose of flu vaccine, by contrast, fetches about $8.

Wyeth left the flu vaccine market entirely last year to focus resources on its more lucrative vaccine.

© 2004 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Most Popular
1
Oil spill reported in North Dakota
2
Texas, N.D. oil push imports down
3
DNO committed to Kurdish oil
4
Deloitte: App downloads dwindle, 1 in 3 users disinterested
5
Gas prices dropping, Energy Department says
Trending News
Video
x
Feedback